How do doctors monitor patients on Kisqali?
Kisqali (ribociclib), a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer, requires regular monitoring for serious risks like low white blood cell counts (neutropenia), liver damage, heart rhythm changes (QT prolongation), and lung issues (interstitial lung disease). Before starting, get baseline tests including complete blood count (CBC), liver function tests (ALT/AST), electrolytes (potassium, calcium, magnesium, phosphorus), ECG, and echocardiogram or multigated acquisition (MUGA) scan for heart function [1][2].
What blood tests happen during treatment?
Check CBC before the first dose of each cycle, on day 15 of cycle 1, and as clinically needed—neutropenia is common (up to 80% of patients) and dose interruptions occur in about 50% [1]. Monitor liver enzymes (ALT/AST) before each cycle start; hold Kisqali if levels exceed 3x upper limit of normal, or 5x in severe cases [2]. Electrolytes get rechecked before each cycle due to QT prolongation risk, especially with drugs like tamoxifen [1].
How often is heart monitoring needed?
Perform ECG before starting and in cycle 2 before dose 15; repeat if QTc exceeds 480 ms or changes by over 60 ms from baseline. Assess left ventricular ejection fraction (LVEF) before cycle 1, cycle 3, and every 6 cycles after via echocardiogram or MUGA—interrupt if LVEF drops below 45% or by 10% from baseline [1][2].
What about lung and other checks?
Monitor for interstitial lung disease/pneumonitis symptoms like cough or shortness of breath; permanent discontinuation is required if confirmed. Pregnancy testing is mandatory for women of reproductive potential before starting and every 2 weeks for the first 2 cycles, then monthly. No routine lung imaging unless symptoms appear [1].
When do adjustments or interruptions happen?
Dose reductions (from 600 mg to 400 mg or 200 mg) are common for toxicities—about 50% of patients need at least one. Interrupt for grade 3/4 neutropenia until recovery to grade ≤2, or for liver/heart issues per specific thresholds. Full discontinuation follows unresolved severe events [2].
[1] Kisqali Prescribing Information, Novartis, accessed via FDA.gov
[2] NCCN Guidelines for Breast Cancer, Version 5.2024 (monitoring protocols align with label)